Publications

cemka > Publications

Classer les publications sur l'année

  • Économie de la santĂ©

    CoĂ»t de l’obĂ©sitĂ© en France

    EMERY C, DINET J, LAFUMA A, SERMET C, KHOSHNOOD B, FAGNANI F

    Presse Med ; 832-840

  • Économie de la santĂ©

    Invasive cervical cancer treatment costs in France

    ARVEUX P, BENARD S, BOUEE S, LAFUMA A, MARTIN L, CRAVELLO L, REMY V, BREUGELMANS JG

    Bull Cancer ; 94(2):219-224

  • Économie de la santĂ©

    CoĂ»t de la prise en charge des frottis anormaux et des nĂ©oplasies intraĂ©pithĂ©liales du col de l’utĂ©rus en France

    BERGERON C, COHET C, BOUEE S, LORANS C, REMY V

    BEH ; (1):4-6

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    Costs of cardiovascular events of diabetic patients in French hospitals

    COLIN X, LAFUMA A, GUERON B

    Diabetes Metab ; 2007;33(4):310-313

  • Économie de la santĂ©

    Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma : analysis conducted on the United Kingdom General Practitioner Research Database

    LAFUMA A, BERDEAUX G

    Curr Med Res Opin ; 23(12):3009-3016

  • Économie de la santĂ©

    Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting

    DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F

    Oncology ; 72:248-254

  • Économie de la santĂ©

    A model of the public health impact of improved treatment persistence in post-meopausal osteoroposis in France

    COTTE FE, CORTET B, LAFUMA A, AVOUAC B, HASNAOUI AE, FADELLONE P, POUCHAIN D, ROUX C, GAUDIN AF

    Joint Bone Spine ; 31

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy

    DENIS PH, LAFUMA A, KHOSHNOOD B, MIMAUD V, BERDEAUX G

    Curr Med Res Opin ; 23(3):601-608

  • Pharmaco-EpidĂ©miologie

    A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment

    ISNARD F, TILLEUL P, LAPORTE JF, CHEVALLIER P, PIGNEUX A, LAFUMA A, MAHI L, DERAY G

    Nephrol Dial Transplant ; 22(10):3090-3091

  • SantĂ© publique

    Evaluation of a screening programme for diabetic retinopathy (DODIA study).

    AUBERT JP, MASSIN P, AUDRAN G, BEN MEHIDI A, BERNIT B, BOUÉE S, BOUHASSIRA M, BOUROVITCH JC, ERGINAY A, ESCHWEGE E, JAMET M, MARRE M, NOUGAIRÈDE M, TCHERNY-LESSENOT S

    Rev Prat. ; 57(11):1203-1209

  • Pharmaco-EpidĂ©miologie

    StratĂ©gie diagnostique de l’infection par le VHC en mĂ©decine gĂ©nĂ©rale : Etats des lieux, nature des obstacles rencontrĂ©s – Etude GYMKHANA 1 (2Ăšme partie)

    AUBERT JP, BOUEE S, BENTATA M, COMPAGNON M, ELGHOZI B, LIVROZET JM, MECHALI D, PERDRIEAU F, PY AM, ROZEMBAUM W, TAULERA O, WAJSBROT A

    Rev Prat - Médecine Générale ; 20(726/727):386-391

  • Pharmaco-EpidĂ©miologie

    Seroprevalence of Varicella in the French Population

    KHOSHNOOD B, DEBRUYNE M, LANCON F, EMERY C, FAGNANI F, DURAND I, FLORET D

    Pediatr Infect Dis J ; 25(1):41-44

  • Pharmaco-EpidĂ©miologie

    Prevalence of visual impairment in relation to the number of ophtalmologists in a given area : a nationwide approach

    LAFUMA A, BREZIN A, FAGNANI F, MESBAH M, BERDEAUX G

    Health and Quality of Life Outcomes ; 4(34)

  • Économie de la santĂ©

    Nonmedical economic consequences attribuables to visual impairment nation-wide approach in France

    LAFUMA A, BREZIN A, FAGNANI F, MIMAUD V, MESBAH M, BERDEAUX G

    Eur J Health Econom ; 7(3):158-164

  • SantĂ© publique

    Management of innovative medicines in hospitals: an international comparison

    LAFUMA A, TILLEUL P

    EJHPP Practice ; 12(1):26-27